Background: The Limiting Antigen-Avidity EIA (LAg-Avidity EIA) is a newly developed HIV-1 incidence assay that was recently validated for plasma specimens for estimation of HIV-1 incidence, a critical end-point measurement to determine the impact of HIV programs. The LAg-Avidity EIA was developed for global use and is available as a kit for use with serum/plasma from two manufacturers. Collection of liquid specimen, processing, storage, and transport are challenging in resource-limited countries and dried blood spots (DBS) are the specimen of choice for surveillance activities. Thus, there is an urgent need for the development and qualification of a LAg-Avidity EIA for use with DBS specimens. Here, we present the evaluation of the Maxim LAg-Avidity DBS EIA for use specifically with DBS specimens. Methodology: A total of 447 matched plasma and DBS specimens were used for this evaluation. Of these, 133 plasma units were purchased from Boca Biolistics (Coconut Creek, FL) and 90 were from Seracare Life Sciences (Milford, MA). Matched DBS were prepared by spotting 100 μl of mock blood (plasma mixed 1:1 with packed red blood cells) onto Whatman 903 filter paper (Whatman plc, United Kingdom). The remaining 224 specimens were collected as unlinked remnant whole blood specimens from HIV-positive patients at an Atlanta-based clinic and matched DBS and plasma were prepared by spotting whole blood onto Whatman 903 filter paper followed by plasma separation. For DBS specimens, 500 μl of specimen diluent was used to elute antibodies overnight from a single 6 mm punch and 100 μl was added to the assay plate. DBS controls were used when testing DBS specimens. All other assay steps remained the same. All plasma and DBS specimens were tested independently by two operators using the Maxim HIV-1 LAg-Avidity EIA (Maxim Biomedical, Rockville, MD) according to the manufacturer’s instructions. Results: Correlation between the DBS and plasma specimens was excellent (R2=0.94) with 85 specimens classifying as recent and 362 as long-term infections with both specimen types (overall agreement 98.6%, kappa=0.956). DBS kit controls were highly reproducible across 26 runs performed by two operators with inter- and intra-run coefficients of variation (%CV) for the low positive control (LPC) and high positive control (HPC) <10%, similar to plasma controls. Inter-operator normalized optical density (ODn) variability between two operators was <10%. Conclusions: This evaluation demonstrates the Maxim LAg-Avidity EIA performs similarly with the DBS or serum/plasma specimens, allowing DBS specimens to be used in surveillance activities for the estimation of HIV incidence. This comprehensive evaluation will further facilitate implementation of LAg-Avidity EIA for cross-sectional incidence estimates.